drugset
drugset / Trial / NCT02371746

Safety and Efficacy of ENV515 Travoprost Extended Release (XR) in Patients With Bilateral Ocular Hypertension or Primary Open Angle Glaucoma

NCT02371746 ↗

Phase 2 Completed 41 enrolled Envisia Therapeutics
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This is a multiple cohort study that will evaluate the safety and efficacy of ENV515 travoprost XR in patients with open-angle glaucoma or ocular hypertension.

Timeline

Start
2015-01-01
Primary completion
2019-02-13
Completion
2019-02-13

Drugs

EvaluationDrugModalityDoseRoute
Subject Travoprost Other / unclassified — Other

Indications

glaucoma